Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and BK polyomavirus (BKV) are the viruses most often implicated in tissue-invasive disease after solid organ transplantation, yet information about their natural history is incomplete. No carefully designed prospective studies exist to characterize posttransplant infections due to CMV, EBV and BKV. The hypothesis is that CMV, EBV and BKV infections and coinfections, even if asymptomatic, cause posttransplant morbidity. The first specific aim is to perform prospective quantitative virology surveillance of renal and lung transplant patients for up to 5 years.
The second aim has substudies to (a) evaluate oral washes and urine as noninvasive alternatives to blood for monitoring viral infections, (b) examine the effects of prophylactic valganciclovir on all 3 viruses;(c) evaluate weekly viral DMAtesting to uncover short-lived infections that may be clinically important (d) provide urine samples for validation of protein markers that distinguish BKV infection and nephrology. CMB, EBV, and BKV DNA will be quantitated by real-time PCR in oral, urine and blood samples at frequent intervals and antibodies to CMV and EBV will be measured. Viral CAN will be quantitated in bronchoalveolar lavage (BAL) samples from lung transplant patients. Donors will be tested at transplant. Quantitative virologic data will be correlated with clinical data from the Research Database of the Kidney and Pancreas Organ Transplant Tracking System, the lung transplant program's O'Brien Biobank and Database, and information from a questionnaire about intercurrent infections. National history characteristics to be examined as predictors, risk factors, and comorbidities include: (1) Baseline CMV and EBV antibody status of donor and recipient. (2) Response to transplant valganciclovir prophylaxis: viral load pre- and post-prophylaxis in oral washes, blood, BAL (lung transplant recipients only) and urine. (3) Serial measurements of CMV, EBV, and BKV viral loads, which will be treated as continuous as well as categorical variables in an analysis of the threshold for developing tissue-invasive disease. Relations of these continuous and categorical natural history characteristics with clinical endpoints will be examined by exploratory graphical methods, cross-classified tables of counts, and comparisons between and within subgroups, and modeled using linear and categorical mixed-effects models for longitudinal measurements. This research will fill a critical gap by identifying risk factors for morbidity due CMV, EBV, and BKV infections that will guide evidence-based strategies for managing these infections.

Public Health Relevance

(Seeinstructions): Relevance to public health: Viral infections are a major complication for the -29,000 patients who receive a solid organ transplant annually in the U.S.
This research aims to define risk factors for posttransplant morbidity due to Cytomegalovirus, Epstein-Barr virus, and BK polyomavirus, which would form the basis for designing scientifically sound management strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK013083-44
Application #
8537413
Study Section
Special Emphasis Panel (ZDK1-GRB-R)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
44
Fiscal Year
2013
Total Cost
$130,835
Indirect Cost
$44,189
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Matas, Arthur J; Vock, David M; Ibrahim, Hassan N (2018) GFR ?25 years postdonation in living kidney donors with (vs. without) a first-degree relative with ESRD. Am J Transplant 18:625-631
Sanchez, Otto A; Ferrara, Laine K; Rein, Sarah et al. (2018) Hypertension after kidney donation: Incidence, predictors, and correlates. Am J Transplant 18:2534-2543
Berglund, Danielle M; Zhang, Lei; Matas, Arthur J et al. (2018) Measured Glomerular Filtration Rate After Kidney Donation: No Evidence of Accelerated Decay. Transplantation 102:1756-1761
Kizilbash, Sarah J; Rheault, Michelle N; Bangdiwala, Ananta et al. (2017) Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis. Pediatr Transplant 21:
Verghese, P S; Schmeling, D O; Filtz, E A et al. (2017) The impact of recipient BKV shedding before transplant on BKV viruria, DNAemia, and nephropathy post-transplant: A prospective study. Pediatr Transplant 21:
Serrano, Oscar Kenneth; Kandaswamy, Raja; Gillingham, Kristen et al. (2017) Rapid Discontinuation of Prednisone in Kidney Transplant Recipients: 15-Year Outcomes From the University of Minnesota. Transplantation 101:2590-2598
Ibrahim, H N; Berglund, D M; Jackson, S et al. (2017) Renal Consequences of Diabetes After Kidney Donation. Am J Transplant 17:3141-3148
Gross, Cynthia R; Reilly-Spong, Maryanne; Park, Taehwan et al. (2017) Telephone-adapted Mindfulness-based Stress Reduction (tMBSR) for patients awaiting kidney transplantation. Contemp Clin Trials 57:37-43
Ibrahim, Hassan N; Foley, Robert N; Reule, Scott A et al. (2016) Renal Function Profile in White Kidney Donors: The First 4 Decades. J Am Soc Nephrol 27:2885-93
Verghese, Priya; Gillingham, Kristen; Matas, Arthur et al. (2016) Post-transplant blood transfusions and pediatric renal allograft outcomes. Pediatr Transplant 20:939-945

Showing the most recent 10 out of 356 publications